Acute effects of linagliptin on progenitor cells, monocyte phenotypes, and soluble mediators in type 2 diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 2, 2016, Pages 748-756

  Fadini, Gian Paolo ^a,b   Bonora, Benedetta Maria ^a   Cappellari, Roberta ^a   Menegazzo, Lisa ^a,b   Vedovato, Monica ^a   Iori, Elisabetta ^a   Marescotti, Maria Cristina ^a   Albiero, Mattia ^a,b   Avogaro, Angelo ^a,b  

^a Division of Metabolic Diseases   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; CD14 ANTIGEN; CD16 ANTIGEN; CD34 ANTIGEN; CHEMOKINE RECEPTOR; FATTY ACID; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INTERLEUKIN 12; LINAGLIPTIN; MACROPHAGE DERIVED CHEMOKINE; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; SCAVENGER RECEPTOR; STROMAL CELL DERIVED FACTOR 1ALPHA; TRIACYLGLYCEROL; VASCULOTROPIN RECEPTOR 2; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETIC NEPHROPATHY; DRUG EFFECT; ENDOTHELIAL PROGENITOR CELL; FATTY ACID BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; MALE; MIDDLE AGED; MONOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; PHENOTYPE; PLEIOTROPY; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; ENDOTHELIUM CELL; METABOLISM; STEM CELL;

AGED; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ENDOTHELIAL CELLS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LINAGLIPTIN; MALE; MIDDLE AGED; MONOCYTES; PHENOTYPE; RENAL INSUFFICIENCY, CHRONIC; STEM CELLS;

EID: 84959386239     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-3716     Document Type: Article

References (35)

1. Fadini GP. A reappraisal of the role of circulating (progenitor) cells in the pathobiology of diabetic complications. Diabetologia. 2014; 57:4-15.
2. Menegazzo L, Albiero M, Avogaro A, Fadini GP. Endothelial progenitor cells in diabetes mellitus. Biofactors. 2012;38:194-202.
3. Fadini GP, Losordo D, Dimmeler S. Critical reevaluation of endothelial progenitor cell phenotypes for therapeutic and diagnostic use. Circ Res. 2012;110:624-637.
4. RigatoM,Bittante C, AlbieroM,Avogaro A, Fadini GP. Circulating progenitor cell count predicts microvascular outcomes in type 2 diabetic patients. J Clin Endocrinol Metab. 2015;100(7):2666-2672.
5. Fadini GP. A look at the bone marrow predicts the global outcome. Circ Res. 2015;116:232-234.
6. Fadini GP, Avogaro A. Potential manipulation of endothelial progenitor cells in diabetes and its complications. Diabetes Obes Metab. 2010;12:570-583.
7. Fadini GP, de Kreutzenberg SV, Boscaro E, et al. An unbalanced monocyte polarisation in peripheral blood and bone marrow of patients with type 2 diabetes has an impact on microangiopathy. Diabetologia. 2013;56:1856-1866.
8. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012;122:787-795.
9. Fadini GP, Cappellari R, Mazzucato M, Agostini C, Vigili de Kreutzenberg S, Avogaro A. Monocyte-macrophage polarization balance in pre-diabetic individuals. Acta Diabetol. 2013;50:977-982.
10. Ceradini DJ, Kulkarni AR, Callaghan MJ, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med. 2004;10:858-864.
11. Proost P, Struyf S, Schols D, et al. Processing by CD26/dipeptidylpeptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal α-Cell-derived factor-1. FEBS Lett. 1998;432:73-76.
12. Fadini GP, Boscaro E, Albiero M, et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromalderived factor-1. Diabetes Care. 2010;33:1607-1609.
13. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, LocatiM. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25:677-686.
14. Fadini GP, Avogaro A. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascul Pharmacol. 2011;55:10-16.
15. Fadini GP, de Kreutzenberg SV, Mariano V, et al. Optimized glycaemic control achieved with add-on basal insulin therapy improves indexes of endothelial damage and regeneration in type 2 diabetic patients with macroangiopathy: a randomized crossover trial comparing detemir versus glargine. Diabetes Obes Metab. 2011;13: 718-725.
16. Levey AS, Stevens LA, Schmid CH, et al. Anew equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-612.
17. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1-S266.
18. Early Treatment Diabetic Retinopathy Study Research Group. GraDing diabetic retinopathy from stereoscopic color fundus photographs-an extension of the modified Airlie House classification. ETDRS report number 10. Ophthalmology. 1991;98:786-806.
19. Fadini GP, Sartore S, Albiero M, et al. Number and function of endothelial progenitor cells as a marker of severity for diabetic vasculopathy. Arterioscler Thromb Vasc Biol. 2006;26:2140-2146.
20. Fadini GP, Albiero M, Menegazzo L, de Kreutzenberg SV, Avogaro A. The increased dipeptidyl peptidase-4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin-treated patients. Diabetes Obes Metab. 2012;14:518-522.
21. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696-1705.
22. Fadini GP, Avogaro A. Dipeptidyl peptidase-4 inhibition and vascular repair by mobilization of endogenous stem cells in diabetes and beyond. Atherosclerosis. 2013;229:23-29.
23. ZarubaMM,TheissHD,VallasterM,et al. Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. Cell Stem Cell. 2009;4:313-323.
24. Wu S, Hopper I, Skiba M, Krum H. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55 141 participants. Cardiovasc Ther. 2014;32: 147-158.
25. Avogaro A, Fadini GP. The effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications. Diabetes Care. 2014;37:2884-2894.
26. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317-1326.
27. Osborn O, Olefsky JM. The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med. 2012;18: 363-374.
28. Thomas G, Tacke R, Hedrick CC, Hanna RN. Nonclassical patrolling monocyte function in the vasculature. Arterioscler Thromb Vasc Biol. 2015;35:1306-1316.
29. Auffray C, Fogg D, Garfa M, et al. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science. 2007;317:666-670.
30. Dal-Secco D, Wang J, Zeng Z, et al. A dynamic spectrum of monocytes arising from the in situ reprogramming of CCR2 monocytes at a site of sterile injury. J Exp Med. 2015;212:447-456.
31. Gee K, Guzzo C, Che Mat NF, Ma W, Kumar A. The IL-12 family of cytokines in infection, inflammation and autoimmune disorders. Inflamm Allergy Drug Targets. 2009;8:40-52.
32. McGill JB, Sloan L, Newman J, et al. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care. 2013;36:237-244.
33. Graefe-Mody U, Friedrich C, Port A, et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab. 2011;13:939-946.
34. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-1305.
35. Choi JH, Kim KL, Huh W, et al. Decreased number and impaired angiogenic function of endothelial progenitor cells in patients with chronic renal failure. Arterioscler Thromb Vasc Biol. 2004;24: 1246-1252.